Skip to content
JKI 22JKI 22JKI 22

Drawing based on the label description. No photo yet.

“22 mg of tofacitinib: Beige, oval, extended-release film-coated tablets with a drilled hole at one end of the tablet band and "JKI 22" printed on one side of the tablet”

JKI22 pill

Pill with imprint JKI22 is brown, oval, 8 mm and has been identified as Tofacitinib 22 mg. It is used for rheumatoid arthritis. It is supplied by U.s. Pharmaceuticals.

Tofacitinib 22 mg

Imprint
JKI22
Strength
22 mg
Used for
Rheumatoid arthritis
Color
Brown
Shape
Oval
Size
8 mm
Score
No score line
Form
Tablet, extended release
Manufacturer
U.s. Pharmaceuticals
Drug class
Cancer medicine (kinase inhibitor)
NDC
63539-502, 63539-502-30, 0069-0502, 0069-0502-30

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Tofacitinib pills and guides

What is Tofacitinib used for?

Tofacitinib is used for rheumatoid arthritis.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Rheumatoid Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Psoriatic Arthritis

Tofacitinib extended-release tablets are indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Ankylosing Spondylitis

Tofacitinib extended-release tablets are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use

Use of tofacitinib extended-release tablets in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

From the FDA-approved label on DailyMed (published Oct 05, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows JKI 22 and the other side has no imprint.
  • It is brown, oval, 8 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Xeljanz.

Ingredients

Active: Tofacitinib Citrate

Inactive: Sorbitol, Hydroxyethyl Cellulose (140 Mpa.s At 5%), Copovidone K25-31, Magnesium Stearate, Cellulose Acetate, Hydroxypropyl Cellulose (1600000 Wamw), Titanium Dioxide, Hypromellose 2910 (6 Mpa.s), Triacetin, Ferric Oxide Red, Shellac, Ammonia, Propylene Glycol, Ferrosoferric Oxide, Fd&c Blue No. 2 Aluminum Lake, Ferric Oxide Yellow

Also distributed by

Pfizer Laboratories Div Pfizer Inc

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Tofacitinib pills